CClinicalTrials.gg
RecruitingNCT06633250RIGHT-GOUpdated Dec 26, 2025

Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy.

An interventional study of Test Formula and Control Formula in Cow Milk Protein Allergy, sponsored by Société des Produits Nestlé (SPN). Recruiting at 19 sites in 3 countries. Open to participants aged Up to 8 Months. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Société des Produits Nestlé (SPN) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
Up to 8 Months
Sex
All
01

Study summary

The main purpose of this study is to demonstrate that the growth of infants fed with the Test Formula is non-inferior those fed with the Control Formula. The study will also evaluate the gastrointestinal tolerance, quatliy of life and acceptability of the new rice protein-based formula in infants with cow's milk protein allergy (CMPA).

02

Conditions studied

  • Cow Milk Protein Allergy
03

In context

Lead sponsor

Société des Produits Nestlé (SPN) is the lead sponsor of 314 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 8 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent has been obtained from at least one parent (or legally acceptable representative [LAR]), if applicable)
  2. Infant gestational age ≥ 37 completed weeks
  3. Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
  4. Singleton birth
  5. Infant age ≤ 8 months
  6. Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk
  7. Suspected CMPA as per standard clinical practice and in conjunction with at least 2 symptoms present from the list shown below:

    1. Inconsolable crying, regurgitation, liquid stools or constipation, skin atopic lesion, cow's milk provoked temporary urticaria/angioedema or vomiting, bloody streaks in stool, or respiratory symptoms
    2. For diagnosis based on either a positive IgE blood test, skin prick test or food challenge, only at least 1 symptom from above list needs to be present
  8. Infant is receiving a strict cow's milk elimination diet and will continue receiving this diet until the completion of the study
  9. Infant's parent(s)/LAR is of legal age of majority, must have parental authority, must understand the informed consent form and other study documents, and is willing and able to fulfill the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  1. History of intolerance to eHF formula
  2. Any chronic medical diseases (except atopic eczema), chromosomal or major congenital anomalies (based on medical history and/or commonly performed diagnostic criteria)
  3. Major gastrointestinal disease / abnormalities (other than CMPA)
  4. Known or suspected lactose intolerance or malabsorption
  5. Known or suspected soy allergy
  6. Glucose-galactose malabsorption
  7. Rice protein allergy or intolerance (e.g., rice protein-induced enterocolitis syndrome).
  8. Immunodeficiency
  9. Persistent wheeze or chronic respiratory disease
  10. Severe uncontrolled eczema
  11. History of severe anaphylactic reaction (e.g., requiring ≥ 2 doses of epinephrine) to cow's milk or breast milk at any time prior to enrollment
  12. Weight-for-age value \< -2 or > 2 standard deviations from the WHO Child Growth Standards median at enrollment
  13. Height-for-age \< -2 or > 2 standard deviations from the WHO Child Growth Standards median at enrollment
  14. Infant's parent has other medical or psychiatric condition that, in the judgement of the investigator, would make the infant inappropriate for entry into the study
  15. Currently participating or having participated in another interventional clinical study within 4 weeks prior to enrollment
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Test Formula

    Hydrolyzed rice protein formula

    Other: Test Formula

  • Active comparator
    Control Formula

    Commercially available extensively hydrolyzed cow's milk formula

    Other: Control Formula

Interventions

  • OtherTest Formula

    Hydrolyzed rice protein formula

  • OtherControl Formula

    Commercially available extensively hydrolyzed cow's milk formula

06

What researchers measure

Primary outcomes

  1. Weight-for-age z-score at 4 months post-enrollment

    Weight measured in g and expressed in z scores according to the World Health Organization (WHO) Child Growth Standards.

    Time frame: From enrollment to 4 months post-enrollment

Secondary outcomes

  1. Weight

    Weight (g and z-scores)

    Time frame: Monthly from enrollment to 4 months post-enrollment

  2. Length

    Length (cm and z-scores)

    Time frame: Monthly from enrollment to 4 months post-enrollment

  3. Head circumference

    Head circumference (cm and z-scores)

    Time frame: At enrollmentn and 4 months post-enrollment

  4. Tibia lenght

    Tibia (cm)

    Time frame: At enrollmentn and 4 months post-enrollment

  5. Femur lenght

    Femur (cm)

    Time frame: At enrollmentn and 4 months post-enrollment

  6. Gastrointestinal Symptoms

    The Infant Gastrointestinal Symptom Questionnaire (IGSQ) will be used to assess GI tolerance. The IGSQ is a validated instrument that includes 13 questions in 5 domains (stooling, spitting-up/vomiting, crying, fussiness, and flatulence) and total scores range from 13 (best) to 65 (worst) for overall GI symptom burden.

    Time frame: Monthly from enrollment to 4 months post-enrollment, and 7 days after enrollment

  7. Gastrointestinal Symptoms

    A daily GI tolerance questionnaire will be used.

    Time frame: First 7 days post enrollment

  8. Stool frequency and consistency

    A retrospective 1-day stool record including the Brussels Infant and Toddler Stool Scale will be used.

    Time frame: At enrollment

  9. Stool frequency and consistency

    A 3-day stool diary including the Brussels Infant and Toddler Stool Scale will be used.

    Time frame: 2 months and 4 months post-enrollment

  10. Cow's Milk-related Allergy Symptom

    The Cow's Milk-related Symptom Score (CoMiSS) will be used to assess symptoms related to CMPA. The CoMiSS questionnaire contains 6 items and generates a score based on gastrointestinal, dermatological, respiratory, and general symptoms (total score range 0-33), which may be associated with CMPA .

    Time frame: Monthly from enrollment to 4 months post-enrollment

  11. Food Allergy Quality of Life

    The Food Allergy Quality of Life Questionnaire (FAQLQ-PF) will be used. It is a validated instrument with 30 items in 3 domains (emotional impact, food-related anxiety, dietary and social restrictions).

    Time frame: At enrollment and 4 months post-enrollment

  12. Parental self-efficacy in managing food allergy

    Parental self-efficacy in managing their child's food allergy will be assessed using the Food Allergy Self-Efficacy Scale for Parents (FASE-P). The FASE-P is a validated instrument with 21 items.

    Time frame: At enrollment and 4 months post-enrollment

  13. Parent-reported infant health-related quality of life

    Parent-reported infant health-related quality of life will be assessed using the Infant and Toddler Quality of Life Questionnaire - Short Form (ITQOL-SF47). The ITQOL-SF47 is a validated instrument with 47 items.

    Time frame: At enrollment and 4 months post-enrollment

  14. Complementary food intake

    Total energy and macronutrient intake calculated from food recalls / diaries.

    Time frame: At enrollment, 2 months post-enrollment and 4 months post-enrollment

  15. Formula compliance

    A questionnaire will be used to assess formula compliance.

    Time frame: Monthly from enrollment to 4 months post-enrollment

  16. Formula liking

    A questionnaire will be used to assess formula liking.

    Time frame: 4 months post-enrollment

  17. Safety - Occurence of AE

    Adverse Events will be collected.

    Time frame: From enrollment to 4 months post-enrollment

07

Study locations

15 of 19 sites recruiting
  • Charité Universitätsmedizin Berlin
    Berlin, Germany
    Recruiting
  • Azienda Ospedaliera Universitaria Federico II
    Naples, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Italy
    • Susanna Esposito, Pr · Contact
    Recruiting
  • AOUP Ospedale Santa Chiara
    Pisa, Italy
    Completed
  • Ospedale Pediatrico Bambino Gesu
    Rome, Italy
    • Vincenzo Fierro, Dr · Contact
    Not yet recruiting
  • AO Ordine Mauriziano
    Turin, Italy
    • Emilia Parodi, Dr · Contact
    Recruiting
  • Poliklinika Ginekologiczno-Położnicza Arciszewscy
    Bialystok, Poland
    • Malgorzata Arciszewska, Dr · Contact
    Recruiting
  • Centrum Medyczne Pratia
    Bydgoszcz, Poland
    • Oleg Warszalewski, Dr · Contact
    Recruiting
  • IN-VIVO Bydgoszcz
    Bydgoszcz, Poland
    • Piotr Korbal, Dr · Contact
    Recruiting
  • Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
    Bydgoszcz, Poland
    • Anna Płoszczuk, Dr · Contact
    Recruiting
  • Vitamed Galaj i Cichomski
    Bydgoszcz, Poland
    • Andrzej Galaj, Dr · Contact
    Recruiting
  • BioMedical Centers
    Janki, Poland
    • Karolina Kolakowska, Dr · Contact
    Recruiting
  • Centrum Medyczne Plejady
    Krakow, Poland
    Completed
  • Jagiellonian University Medical College
    Krakow, Poland
    • Urszula Jedynak-Wasowicz, Dr · Contact
    Recruiting
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika
    Lodz, Poland
    • Agnieszka Brzozowska, Dr · Contact
    Recruiting
  • ETG Lublin
    Lublin, Poland
    • Zofia Bartnik, Dr · Contact
    Recruiting
  • Korczowski Bartosz Gabinet Lekarski
    Rzeszów, Poland
    • Bartosz Korczowski, Pr · Contact
    Recruiting
  • Alergo-Med Specjalistyczna Przychodnia Lekarska
    Tarnów, Poland
    • Bernadetta Majorek-Olechowska · Contact
    Recruiting
  • University Hospital of Warsaw
    Warsaw, Poland
    Completed
08

References and documents

Publications

  • Zemrani B, Hays NP, Darwish N, Beyer K, Berni Canani R, Szajewska H; RIGHT-GO Consortium. Growth and safety of infants with cow's milk allergy receiving a new hydrolyzed rice protein-based formula containing 2-fucosyllactose and lacto-N-neotetraose: protocol for a randomized clinical trial. The RIGHT-GO study. Front Nutr. 2026 Apr 24;13:1784490. doi: 10.3389/fnut.2026.1784490. eCollection 2026. PubMed 42111853 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06633250
Lead sponsor
Société des Produits Nestlé (SPN)
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Oct 25, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Anthony de COZAR
Contact
anthony.decozar@rd.nestle.com
+41762627426

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion